Login to Your Account

Earnings Roundup

Friday, April 20, 2012

• Cubist Pharmaceuticals Inc., of Lexington, Mass., reported total net revenues of $211.7 million for the first quarter. Sales of Cubicin (daptomycin for injection), an antibiotic, totaled $197.4 million worldwide, with $184.7 million of that in the U.S. Sales of Entereg (alvimopan), a mu opioid receptor antagonist with gastrointestinal indications that Cubist gained in its December 2011 acquisition of Adolor Corp., totaled $9.4 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription